US Stock MarketDetailed Quotes

DVAX Dynavax Technologies

Watchlist
  • 11.210
  • +0.040+0.36%
Close Apr 26 16:00 ET
  • 11.210
  • 0.0000.00%
Post 16:13 ET
1.47BMarket Cap-224200P/E (TTM)

About Dynavax Technologies Company

Dynavax Technologies Corp. operates as a biopharmaceutical company, which engages in the discovery, development, and commercialization of novel vaccines and immuno-oncology therapeutics. Its product includes HEPLISAV-B, which prevents infection caused by all known subtypes of hepatitis B virus in adults 18 years of age and older. The company was founded by Lawrence M. Lichtenstein, Dennis A. Carson, and Eyal Raz on August 29, 1996 and is headquartered in Emeryville, CA.

Company Profile

SymbolDVAX
Company NameDynavax Technologies
Listing DateFeb 19, 2004
Issue Price7.50
Founded1996
CEOMr. Ryan Spencer
MarketNASDAQ
Employees408
Securities TypeOrdinary Shares
Fiscal Year Ends12-31
Address2100 Powell Street,Suite 900
CityEmeryville
ProvinceCalifornia
CountryUnited States of America
Zip Code94608
Phone1-510-848-5100
Websitehttp://www.dynavax.com

Company Executives

  • Name
  • Position
  • Salary
  • Ryan Spencer
  • Interim Chief Financial Officer, Chief Executive Officer and Director
  • 5.59M
  • Kelly MacDonald
  • Senior Vice President and Chief Financial Officer
  • 1.79M
  • David Novack
  • President and Chief Operating Officer
  • 2.78M
  • Dr. Robert Janssen, M.D.
  • Chief Medical Officer and Senior Vice President, Clinical Development, Medical and Regulatory Affairs
  • 1.71M
  • Justin Burgess
  • Controller and Chief Accounting Officer
  • --
  • John L. Slebir
  • Senior Vice President and General Counsel
  • --
  • Scott D. Myers
  • Chairman of the Board
  • 323.73K
  • Brent MacGregor
  • Independent Director
  • 278.73K
  • Peggy V. Phillips
  • Independent Director
  • 298.73K
  • Julie M. Eastland
  • Independent Director
  • 293.73K
  • Elaine D. Sun
  • Independent Director
  • 278.73K
  • Dr. Daniel L. Kisner, M.D.
  • Independent Director
  • 290.73K
  • Dr. Francis R. Cano, PhD
  • Independent Director
  • 278.73K
  • Dr. Peter R. Paradiso, PhD
  • Independent Director
  • 277.73K

Analysis

Analyst Rating

No Data

Price Target

No Data

Heat List
US
Overall
Symbol
Latest Price
%Chg